Becton, Dickinson and Company (NYSE:BDX) had its price target boosted by Morgan Stanley from $205.00 to $245.00 in a report issued on Friday. The brokerage currently has an “equal weight” rating on the medical instruments supplier’s stock. Morgan Stanley’s price objective points to a potential upside of 9.18% from the stock’s current price.

Several other research firms have also recently weighed in on BDX. Royal Bank Of Canada reiterated a “sector perform” rating and set a $230.00 price objective (up previously from $210.00) on shares of Becton, Dickinson and in a research report on Friday. Wells Fargo & Company reiterated a “positive” rating and set a $235.00 price objective (up previously from $225.00) on shares of Becton, Dickinson and in a research report on Tuesday, October 24th. They noted that the move was a valuation call. Zacks Investment Research upgraded Becton, Dickinson and from a “sell” rating to a “hold” rating in a research report on Friday, October 20th. Bank of America Corporation reiterated a “buy” rating and set a $225.00 price objective (up previously from $200.00) on shares of Becton, Dickinson and in a research report on Friday, July 21st. Finally, Piper Jaffray Companies reiterated a “buy” rating and set a $213.00 price objective on shares of Becton, Dickinson and in a research report on Tuesday, September 12th. Five equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $213.47.

Becton, Dickinson and (NYSE:BDX) traded up $0.39 during mid-day trading on Friday, reaching $224.41. The company’s stock had a trading volume of 1,405,516 shares, compared to its average volume of 1,325,794. The company has a quick ratio of 5.01, a current ratio of 5.56 and a debt-to-equity ratio of 1.48. The company has a market cap of $51,067.86, a PE ratio of 23.65, a price-to-earnings-growth ratio of 1.78 and a beta of 1.04. Becton, Dickinson and has a 1 year low of $161.29 and a 1 year high of $224.89.

Becton, Dickinson and (NYSE:BDX) last posted its quarterly earnings data on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share for the quarter, topping the consensus estimate of $2.37 by $0.03. The firm had revenue of $3.17 billion for the quarter, compared to analysts’ expectations of $3.14 billion. Becton, Dickinson and had a return on equity of 22.51% and a net margin of 8.52%. The company’s quarterly revenue was down 2.0% compared to the same quarter last year. During the same quarter last year, the business earned $2.12 EPS. equities research analysts expect that Becton, Dickinson and will post 10.6 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Becton, Dickinson and Company (BDX) Price Target Increased to $245.00 by Analysts at Morgan Stanley” was originally posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/11/05/becton-dickinson-and-company-bdx-price-target-increased-to-245-00-by-analysts-at-morgan-stanley.html.

In other Becton, Dickinson and news, insider Gary M. Cohen sold 15,512 shares of Becton, Dickinson and stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $203.77, for a total value of $3,160,880.24. Following the transaction, the insider now owns 95,781 shares in the company, valued at $19,517,294.37. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Stephen Sichak sold 11,787 shares of Becton, Dickinson and stock in a transaction dated Friday, September 8th. The shares were sold at an average price of $200.46, for a total value of $2,362,822.02. Following the completion of the transaction, the insider now owns 14,038 shares in the company, valued at approximately $2,814,057.48. The disclosure for this sale can be found here. In the last quarter, insiders sold 75,904 shares of company stock worth $15,242,688. Company insiders own 1.40% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its stake in shares of Becton, Dickinson and by 8.5% during the second quarter. Vanguard Group Inc. now owns 17,255,948 shares of the medical instruments supplier’s stock valued at $3,366,809,000 after purchasing an additional 1,353,780 shares in the last quarter. BlackRock Inc. boosted its stake in shares of Becton, Dickinson and by 2,427.8% during the first quarter. BlackRock Inc. now owns 16,542,028 shares of the medical instruments supplier’s stock valued at $3,034,470,000 after purchasing an additional 15,887,611 shares in the last quarter. State Street Corp boosted its stake in shares of Becton, Dickinson and by 3.5% during the second quarter. State Street Corp now owns 10,270,221 shares of the medical instruments supplier’s stock valued at $2,003,834,000 after purchasing an additional 342,873 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Becton, Dickinson and by 6.5% during the first quarter. JPMorgan Chase & Co. now owns 3,967,843 shares of the medical instruments supplier’s stock valued at $727,863,000 after purchasing an additional 242,081 shares in the last quarter. Finally, Northern Trust Corp boosted its stake in shares of Becton, Dickinson and by 4.0% during the second quarter. Northern Trust Corp now owns 2,813,937 shares of the medical instruments supplier’s stock valued at $549,028,000 after purchasing an additional 106,966 shares in the last quarter. Hedge funds and other institutional investors own 86.70% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Analyst Recommendations for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.